 |
市场调查报告书
商品编码
1358082
病毒性结膜炎治疗药物市场：依药物类别、按病毒类型、按配销通路、按地区Viral Conjunctivitis Drugs Market, By Drug Class, By Virus Type (Adenovirus, Enterovirus, Others ), By Distribution Channel, By Geography |
||||||
预计2023年，全球病毒性结膜炎治疗药物市值为3.225亿美元，预计在预测期内（2023-2030年）年复合成长率为5.1%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 3.225 亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期年复合成长率 | 5.10% | 2030年市场规模预测 | 4.567 亿美元 |
病毒性结膜炎是由多种病毒引起的急性结膜感染疾病，包括腺病毒和单纯疱疹病毒。病毒性结膜炎占感染性结膜炎的大部分，占病例的75%。病毒性结膜炎的特征包括发红、红血管、眼睛分泌物、疼痛和畏光。由腺病毒群引起的病毒性结膜炎称为流行性角结膜炎（EKC）。这群腺病毒有不同的血清型，也可能引起咽结膜热和特异性滤泡性结膜炎。根据《美国眼科学会：2021》发表的一篇论文，腺病毒性结膜炎是成年人中最常见的眼部感染疾病类型。腺病毒结膜炎具有高度传染性，引起感染的病毒可以在檯面和其他表面上存活数週。
市场动态
市场参与者正在进行各种无机活动，例如公司收购、产品核可和其他活动，预计这些活动将在预测期内推动全球病毒性结膜炎治疗药物市场的成长。例如，2020 年 2 月，Bausch Health Companies Inc. 和製药公司的全资子公司 Eton Pharmaceuticals, Inc. 宣布已获得 Eton Pharmaceuticals 在临床实验滴眼剂 EM-100 的美国权利。如果核准，该滴眼剂将成为第一种用于治疗与结膜炎相关的眼睛搔痒的非处方（OTC）不含防腐剂的滴眼剂。
此外，2020年7月，全球眼科护理领导者爱尔康宣布，Pataday Once Daily Relief Extra Strength（盐酸奥洛他定眼用溶液0.7%）（原处方为Pazeo）已获得美国食品药物管理局批准，作为过度治疗药物。美国非处方药（FDA）宣布已获核准。 Pataday Once Daily Relief Extra Strength 是第一个也是唯一一个每天一次的滴眼液，无需处方笺即可提供 24 小时缓解眼睛瘙痒的效果。过敏是美国慢性病的第六大原因，非处方药零售额约 27 亿美元。
本研究的主要特点
- 该报告对全球病毒性结膜炎治疗药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率(CAGR)。它揭示了各个细分市场的潜在商机，并说明了市场有吸引力的投资提案矩阵。
- 它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球病毒性结膜炎治疗药物市场的主要企业。
- 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
- 全球病毒性结膜炎治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 相关人员可以透过用于分析全球病毒性结膜炎治疗药物市场的各种策略矩阵来促进决策。
目录
第1章调查目的和假设
- 这项研究的目的
- 假设
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第3章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 市场机会
- 影响分析
- 最近测试启动
- 流行病学
- 合併、收购和合作
- 法规场景
- 主要进展
- PEST分析
第4章全球病毒性结膜炎治疗药物市场－新型冠状病毒感染疾病（COVID-19）影响分析
- 经济影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 对需求和供给的影响
第5章全球病毒性结膜炎治疗药物市场：依药物类别，2018-2030
- 抗生素
- 人工泪液
- 减充血剂
- 抗组织胺药
- NSAIDs
- 抗病毒药物
- 其他的
第6章全球病毒性结膜炎治疗药物市场：依病毒类型，2018-2030
- 腺病毒
- 肠病毒
- 其他（单纯疱疹病毒（HSV）等）
第7章全球病毒性结膜炎治疗药物市场：依配销通路，2018-2030
- 医院药房
- 零售药房
- 网路药房
第8章全球病毒性结膜炎治疗药物市场：按地区划分，2018-2030年
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章竞争形势
- 公司简介
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.mbH
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson &Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.
第10章章
- 参考
- 调查方法
The global viral conjunctivitis drugs market is estimated to be valued at US$ 322.5 million in 2023 and is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 322.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 5.10% | 2030 Value Projection: | US$ 456.7 Mn |
Viral conjunctivitis is an acute conjunctival infection that is caused by various viruses, such adenovirus, herpes simplex virus, etc. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases. Characteristics of ocular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia, etc. Viral conjunctivitis that is caused by a group of adenoviruses is called epidemic keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2021, adenoviral conjunctivitis is the most common type of eye infection in the adult population. Adenoviral conjunctivitis is highly contagious, as the virus causing the infection can survive on a countertop or a similar surface for several weeks.
Market Dynamics
Market players are engaged in various inorganic activities such as acquisitions of companies, product approval, and others, which in turn is expected to drive growth of the global viral conjunctivitis drugs market over the forecast period. For instance, on February 2020, Bausch Health Companies Inc.'s wholly owned subsidiary, Eton Pharmaceuticals, Inc., a pharmaceutical company, announced that they had acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, would be the first over-the-counter (OTC) preservative-free formulation eye drop to be used for the treatment of ocular itching associated with conjunctivitis.
Furthermore, in July 2020, Alcon, the global leader in eye care, announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, had been approved by the U.S. Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the U.S. Pataday Once Daily Relief Extra Strength is the first and only once-daily eye allergy itch drop offering a full 24 hours of relief without a prescription. Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately US$ 2.7 billion in OTC retail sales.
Key features of the study:
- This report provides an in-depth analysis of the global viral conjunctivitis drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global viral conjunctivitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral conjunctivitis drugs market.
Detailed Segmentation:
- By Drug Class:
- Antibiotics
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Others (Steroids, etc.)
- By Viral Type:
- Adenovirus
- Enterovirus
- Others (Herpes Simplex Virus (HSV), etc.)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Virus Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Viral Conjunctivitis Drugs Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Artificial tears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Decongestants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Anti-histamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- NSAIDS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Anti-Viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Mn)
- Segment Trends
6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Adenovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Enterovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Others (Herpes Simplex Virus (HSV), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Viral Conjunctivitis Drugs Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bausch Health Companies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Panoptes Pharma Ges.m.b.H
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- NovaBay Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Nicox, NanoViricides Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Santen Pharmaceutical Co.Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alcon
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Okogen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
10. Section
- References
- Research Methodology
- About us and Sales Contact
